SCHEMBL830281

SCHEMBL830281

COc1ccc(NS(=O)(=O)c2cc3c(Br)cc(Br)cc3[nH]c2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
LMNA P02545 5/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 4/20 0.44
POLB P06746 2/20 0.44
HTT P42858 1/20 0.41
BCL2L1 Q07817 1/20 0.41
MCL1 Q07820 1/20 0.41
IDO1 P14902 1/20 0.41
MAPT P10636 2/20 0.41
THRB P10828 2/20 0.41
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
SGK1 O00141 1/20 0.40
CYP19A1 P11511 1/20 0.40
KIT P10721 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830865 0.89 POLB (0.48) BRD4LMNATP53POLBHTT
SCHEMBL831307 0.80 PARK7 (0.41) POLBTHRB
SCHEMBL5432794 0.78 FFAR4 (0.37) BRD4LMNAPOLBMAPTSGK1
SCHEMBL830383 0.78 PIM1 (0.42) CYP19A1
SCHEMBL830382 0.78 PIM1 (0.42) CYP19A1
SCHEMBL831859 0.78 PIM1 (0.42) CYP19A1
SCHEMBL830117 0.76 KDM4E (0.58) BRD4LMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL830013 0.74 PIM1 (0.39) CYP19A1
SCHEMBL830014 0.74 PIM1 (0.39) CYP19A1
SCHEMBL831273 0.74 PGR (0.51) BRD4LMNAALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 BRD4 296/4885LMNA 2758/4885ALDH1A1 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.